SBIR/STTR Research Award
PlusOne: Prototyping and Validation of a Wireless In-Home Breathing Monitor for Prevention of Overdose Deaths
Award amount
$225,000Program and phase
STTR · Phase IAward year
2016Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Xandem Technology LLC
- Proposal award date
- 2016-04-01
- Contract end date
- 2018-03-31
- UEI
- Not reported
- Solicitation number
- PA15-270
- Topic code
- NIDA
Research abstract
DESCRIPTION provided by applicant This proposal investigates the use of a novel passive personal monitoring system to stem the tide in the epidemic of deaths due to unintentional opioid drug overdoses In the U S in opioid drug overdoses including prescription pain relievers and heroin caused deaths a number that has increased dramatically over the past two decades A person who overdoses on an opioid drug can have their breathing slow and then stop during sleep leading to anorexic brain damage or death We propose PlusOne a non contact whole home breathing monitor that is always on and provides early detection of severe respiratory depression and sends an alert in time for intervention to prevent death The overall goal of this project is to develop a beta prototype and to validate the technology in human subject studies This validation will provide the foundation for early commercialization of a consumer respiratory monitor and provide the background for future clinical trials performed in Phase II in order to request FDA regulatory approval for a clinical device Currently at risk
patients who live or sleep alone are at high risk for overdose death because periodic visits or monitoring is insufficient to detect an overdose soon enough to prevent death No other non contact breathing sensor or wearable sensor provides robust protection as people donandapos t plan an overdose and thus donandapos t plan to wear or position themselves to be monitored after an overdose PlusOne has been tested with bench studies and preliminary human subject studies The device has shown that it is accurate to within bpm compared to a current clinical standard capnograph and that it can monitor breathing across an entire home The steps outlined in this Phase I proposal will validate the feasibility of the technology through successful development and implementation of real time processing algorithms a human subject study performed on sleeping individuals with sleep conditions i e obstructive sleep apnea restless leg syndrome etc and month long deployments in the homes of healthy subjects Successful completion of these aims will provide verification and validation of the robustness of the solution we propose as well as the commercial viability for deployment in the homes of at risk individuals By initially targeting the market of patients in or recently in rehabilitation treatment we believe PlusOne can achieve a $ million annual revenue and decrease unintentional opioid drug overdose deaths by more than
PUBLIC HEALTH RELEVANCE In drug overdoses caused deaths in the US half were due to prescription medications including from prescription opioid medications Opioid drugs inhibit the bodyandapos s breathing processes causing respiration to be depressed or stop completely We will develop PlusOne a radio frequency based whole home non contact breathing monitor that sends alerts to caretakers or if a personandapos s breathing rate falls to a dangerously low level within the home providing an opportunity to save the personandapos s life
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Wearable Wireless Respiratory Monitoring System that Detects and Predicts Opioid Induced Respiratory Depression
- Building and testing the Life Enhancement and Advocacy Programming digital training tool (LEAPLink) to better serve people with lived experience of homelessness and substance use disorder
- A digital intervention to decrease self-stigma among pregnant and postpartum women with opioid use disorder
- Development of medication for the treatment of respiratory depression due to opioid (prescribed or illicit) overdose/multidrug (polysubstance) overdose in a hospital or community setting.
- Creation and Validation of the Dose-Opioid-Source Evaluation tool (DOSE) - a Robust Opioid Use Clinical Outcome Assessment for Qualification as an FDA Medical Device Development Tool (MDDT)